Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 51

Results For "CCO"

1766 News Found

Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
News | May 30, 2025

Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr

The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago


Alkem reports 7.1% YoY revenue growth in Q4 FY25
News | May 30, 2025

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points


Venus Remedies joins United Nations Global Compact
Sustainability | May 21, 2025

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery


Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
News | May 18, 2025

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis


Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
News | May 16, 2025

Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025


Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
Drug Approval | May 14, 2025

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy


LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa
News | May 13, 2025

LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa

Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership


Suven Pharmaceuticals is now Cohance Lifesciences
News | May 08, 2025

Suven Pharmaceuticals is now Cohance Lifesciences

The change of name has been carried on pursuant to the Scheme of Amalgamation


GMM Pfaudler Group appoints Gregory Gelhaus as Chief Transformation Officer
People | May 06, 2025

GMM Pfaudler Group appoints Gregory Gelhaus as Chief Transformation Officer

Gelhaus has a proven track record of driving business growth